〔Abstract〕 Objective To evaluate the clinical effectiveness of transcutaneous electrical acupoint stimulation(TEAS) in the treatment of sequelae of inflammatory pelvic diseases in women. Methods A total of 100 patients diagnosed with sequelae of inflammatory pelvic diseases were selected. They were randomly divided into three groups: transcutaneous electrical acupoint stimulation(TEAS) treatment group(40 cases), drug treatment group(30 cases) and combined treatment group(30 cases). The three groups received treatment for four weeks: the medication group received Kangfu xiaoyan shuan; the combination treatment group received TEAS combined with Kangfu xiaoyan shuan; and the TEAS treatment group received the highest level of electrical stimulation that the human body could withstandviamedium-low frequency pulsed electrotherapy instrument on the Guanyuan acupoints or the uterine acupoints. Prior to and following treatment, the three patient groups′ local sign score, symptom and sign score(McCormack score), visual analogue scale(VAS) score for lower abdomen pain, and SF-36 scale score were observed. Additionally, the three groups′ incidence of adverse events was noted. Results Following the intervention, all three groups′ local sign score, McCormack score, and VAS score for lower abdomen pain were considerably lower than they were before the intervention(P<0.05). These three scores showed significant differences(P<0.05) between the combination treatment group and the TEAS treatment and drug treatment groups. The combined treatment group′s scores were lower. The three groups′ total somatic health score and total mental health score before and after the intervention differed significantly(P<0.05) after the period of therapy. Additionally, the combined treatment group′s total somatic health score and total mental health score were higher than those of the medication group. In all three groups, there were no notable negative reactions. Conclusion TEAS treatment is effective in relieving the symptoms of chronic pelvic pain due to the sequelae of inflammatory pelvic disease, and the combination of medication is better than monotherapy in improving pain symptoms and quality of life.